Details of the Drug Combination

General Information of Drug Combination (ID: DC1JE83)

• Drug Combination Name: PF-562271 + Eltanexor oral
• Indication: Hodgkin lymphoma; Status: Investigative [1]
• Component Drugs:
  PF-562271 (DMSLE03): Small molecular drug
  Eltanexor oral (DM7CLEZ): N.A.
• High-throughput Screening Result:
  Testing Cell Line: U-HO1
  Zero Interaction Potency (ZIP) Score: 30.26
  Bliss Independence Score: 31.16
  Loewe Additivity Score: 11.3
  LHighest Single Agent (HSA) Score: 14.92

Molecular Interaction Atlas of This Drug Combination

Indication(s) of PF-562271

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

PF-562271 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Focal adhesion kinase 1 (FAK)	TTON5IT	FAK1_HUMAN	Inhibitor	[4]

Indication(s) of Eltanexor oral

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 1/2	[3]
Myelodysplastic syndrome	2A37	Phase 1/2	[3]
Prostate cancer	2C82.0	Phase 1/2	[3]

Eltanexor oral Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Exportin-1 (XPO1)	TTCJUR4	XPO1_HUMAN	Inhibitor	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT00666926) Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.